The Biotech industry remains increasing prices on large-cap biotech. It also believes that with the recent drug-pricing related sentiment turn, biotech’s Q315 performance is likely to be criticized much more than quarters past. While we don’t pretend to know where sentiment will discover its nadir, we do think valuations are quickly becoming too enticing to turn away. This is especially true with the backdrop of still largely robust commercial views. We see the best upside potential from Strong Buy rated with biotech stocks such as Progressive Care Inc (OTCMKTS:RXMD), RXi Pharmaceuticals Corp (NASDAQ:RXII), SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF).
Progressive Care Inc (OTCMKTS:RXMD), through its subsidiary PharmCo, LLC, is a South Florida provider of prescription pharmaceuticals working in health practice risk management, the sale of anti-retroviral medications and related medication therapy treatment, the sale and rental of reliable medical equipment and the demand of prescription medications to long-term care facilities.The pharmacy filled over 17,000 prescriptions during the month, which is close to 30% increase over the same month this past year and close to 4% higher than this past month. Moving along the third quarter of this year, PharmCo filled over 50,000 prescriptions documenting the best sales quarter for the company to date. Tuesday RXMD saw gains of 73% from Monday’s close giving them a push in the right direction.
SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) whose headquarters are located in Rehovot Israel, is in the business of developing, manufacturing and promoting biological products for human healthcare. The Company’s flagship product, Sci‐B‐Vac™, is a recombinant 3rd generation hepatitis B vaccine. SVACF releases details that its wholly-owned subsidiary SciVac Ltd. (the “Company”) has obtained a green light from the Israeli Ministry of Health to continue all standard manufacturing, including labeling and release of Sci-B-Vac™ to the market, following corrective actions to the automated labeling system and an inspection of the Company’s facilities earlier in the month of September. SVACF is up from last Fridays close with and an increase of 13% creating momentum for the future of this biotech stock.
RXi Pharmaceuticals Corp (NASDAQ:RXII) is a biotech company dedicated to discovering and creative innovative therapeutics primarily in the areas of dermatology and ophthalmology that identifies high-unmet medical needs. Our discovery and clinical development systems are based on siRNA technology as well as immunotherapy agents. These compounds involve, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. RXII is biotech stock that has seen significant gains amounting to an increase of 74.5% since the end of September till Tuesday highs making them penny stock to watch moving into the new year